Drug intelligence / Profile preview

gabapentin + venlafaxine

Development stage
Unknown
Lead developer
Pfizer
Modality
Small Molecules
Administration
Oral
01

Overview

Gabapentin + venlafaxine is a combination of two pharmaceutical drugs, gabapentin and venlafaxine, used primarily in the management of neuropathic pain and certain psychiatric or somatic symptom disorders. Gabapentin is an anticonvulsant that modulates voltage-gated calcium channels to reduce excitatory neurotransmitter release, while venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases synaptic concentrations of serotonin and norepinephrine by inhibiting their reuptake at presynaptic terminals. This combination has been studied for enhanced efficacy in patients with neuropathic pain who do not respond adequately to monotherapy with either agent. Some studies report improved pain control, mood disturbance, and quality of life when both drugs are used together; however, there may be negative pharmacodynamic interactions under certain conditions[1][3][4].

02

Targets

CACNA2D2 (α2δ-2)DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on gabapentin + venlafaxine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on gabapentin + venlafaxine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call